Sort
23,748 grants matching “melanoma”
Development
$403,724William L. Carroll · New York University School Of Medicine · P30 · FY2009 · CA
Immune Aging in Responsiveness to Checkpoint Blockade Immunotherapies
$403,645Vandana Kalia · Seattle Children'S Hospital · R56 · FY2022 · AG
Applying Genomic Dosimeters of UV Damage to Predicting Skin Cancer Risk
$403,641Douglas E Brash · Yale University · R01 · FY2024 · ES
NK cell exhaustion in metastatic melanoma
$403,630Nina Bhardwaj · Icahn School Of Medicine At Mount Sinai · R01 · FY2016 · CA
Deciphering MDSC function for GBM targeting
$403,517Justin D. Lathia · Cleveland Clinic Lerner Com-Cwru · R01 · FY2020 · NS
EGFRvIII-targeted Bispecific T cell Engagers for brain tumors
$403,487John H Sampson · Duke University · R01 · FY2016 · NS
Reprogramming the Tumor Microenvironment to Improve Immunotherapy of Glioblastoma by Co-Targeting VEGF and Ang2
$403,419Dai Fukumura · Massachusetts General Hospital · R01 · FY2023 · NS
Reprogramming the tumor microenvironment to improve immunotherapy of glioblastoma by co-targeting VEGF and Ang2
$403,419Dai Fukumura · Massachusetts General Hospital · R01 · FY2022 · NS
Reprogramming the tumor microenvironment to improve immunotherapy of glioblastoma by co-targeting VEGF and Ang2
$403,419Dai Fukumura · Massachusetts General Hospital · R01 · FY2021 · NS
Regulation of stem-like CD8+ T cells and their role in immunotherapy
$403,393Ana C Anderson · Brigham And Women'S Hospital · R01 · FY2025 · CA
Regulation of stem-like CD8+ T cells and their role in immunotherapy
$403,366Ana C Anderson · Brigham And Women'S Hospital · R01 · FY2022 · CA
Determining the clinical impact of gene expression testing in localized prostate cancer
$403,307Todd M. Morgan · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
Project 3: Predicting therapeutic sensitivity in cancer
$403,256Anna Lasorella · Columbia University Health Sciences · U54 · FY2015 · CA
UCHL5 as a regulator and therapeutic target in metastatic melanoma
$403,230Kunal Rai · University Of Tx Md Anderson Can Ctr · R01 · FY2023 · CA
UCHL5 as a regulator and therapeutic target in metastatic melanoma
$403,228Kunal Rai · University Of Tx Md Anderson Can Ctr · R01 · FY2022 · CA
A redox-mediated mechanism of UVB-induced metabolic switch in skin carcinogenesis
$403,205Daret K St Clair · University Of Kentucky · R01 · FY2022 · CA
Administrative Core
$403,118Bruce E. Johnson · Dana-Farber Cancer Inst · U2C · FY2021 · CA
The Unique Roles of Tumor-Specific Th9 Cells for Solid Tumor Eradication
$403,102Yong Lu · Methodist Hospital Research Institute · R01 · FY2022 · CA
Patterning of the Vertebrate Nervous System
$402,986Sergei Y Sokol · Icahn School Of Medicine At Mount Sinai · R01 · FY2015 · NS
ATF2 in melanoma development and progression
$402,953Ze'ev A Ronai · Sanford Burnham Prebys Medical Discovery Institute · R01 · FY2007 · CA
Individualized monitoring of treatment response and resistance in patients with metastatic melanoma
$402,872Muhammed Murtaza · Translational Genomics Research Inst · R01 · FY2019 · CA
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss
$402,857Tal Teitz · Creighton University · R01 · FY2021 · DC
Repurposing an FDA approved Drug, B-Raf Kinase Inhibitor Dabrafenib for Protection from Cisplatin- and Noise- induced Hearing Loss
$402,857Tal Teitz · Creighton University · R01 · FY2023 · DC
Project 3: Inhibiting Oxidative Phosphorylation in Pancreatic Cancer
$402,801Shubham Pant · University Of Tx Md Anderson Can Ctr · P50 · FY2020 · CA
Targeting Lag-3 and PD -1 in Myeloid Cells of GBM
$402,791Michael Lim · Stanford University · R01 · FY2022 · NS